Jing Cheng Diabetes Medical Closes on ￥3.12M Angel Round

Hunan Jingcheng Diabetes Medical Technology Co., Ltd. ("Jingcheng Diabetes Medical") has formally signed a strategic investment agreement with an investment company and has got 3.12 million yuan in the angel round financing, accounting for 5.2% of the shares. Jingcheng Diabetes Medical is valued at 60 million yuan after this financing. Proceeds of this fund will mainly be used for market development and follow-up research and development of Jing Cheng's overall solution for diabetes biomedicine, to provide diabetes treatment more efficiently.

Established in March 2019, Jingcheng Diabetes Medical is a provider of integrated solutions through stem cell nutrition intervention based on biomedicine. Relying on traditional Chinese medicine clinics, Jingcheng Diabetes Medical provides service for diabetic patients and builds a database system to collect data for future artificial intelligence optimization. Up to now, Jincheng Diabetes Medical has successfully helped nearly 500 diabetic patients without western medicine or injection to achieve low blood sugar or recovery. 

Jingcheng Diabetes Medical plans to further upgrade its business model, and build an ecosystem of "Internet + big data + diabetes chain hospitals + diabetes chain stores+ diabetes research institutes + diabetes public welfare fund", so as to provide comprehensive services for patients.

Liu Jiayin, the founder of Jingcheng Diabetes Medical, said that the company in China and is going to be listed in 3 to 5 years to become the first listed firm in the field of diabetes.

Ms. Chen, the representative of the investment firm, said that there are about 140 million people with diabetes in China, and the estimated market size is one trillion yuan. The effective treatment of diabetes with biomedicine will not only be market with large demands but also has important social value.